Nairobi, August 23: Malaria still threats human race especially in some countries of Africa it is still highly prevalent. For a new anti-malaria drug, trials will be held across nine countries in Africa and Asia. In next couple of months, Kenya will hold trials for KAF156, developed by Swiss pharmaceutical company Novartis.
"To build on the gains made against malaria since the turn of the century, we need new medicines that are effective across all types of resistance patterns and geographies, and that are easy to administer, especially to children," Dr. David Reddy, the chief executive officer of Medicines for Malaria Venture (MMV) said.
To achieve malaria elimination, innovation is very much needed. Innovation could be the best weapon against this disease. Kenyan Health Ministry also set up an online portal to track drug resistance in the country.